Neurogastrx rakes in $60m Series B
Neurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.
Neurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination